Introduction: The use of multiagent chemotherapy in acute lymphoblastic leukemia (ALL) has resulted in improvement in overall survival (OS), albeit to a different extent across various age groups. This large database study aims to assess the disparity in the utilization of chemotherapy in ALL in the real-world setting. Materials and methods: Using the Surveillance, Epidemiology, and End Results database, patients with ALL diagnosis from 2006 to 2016 were identified. Baseline characteristics were compared between the groups who did vs. did not receive chemotherapy using χ2 test. Multivariable logistic regression was used to evaluate the association between various sociodemographic factors and the receipt of chemotherapy in the entire cohort ...
Acute lymphoblastic leukemia (ALL) has poor prognosis in older/elderly adults and in high-risk/relap...
The outcome of children and adults with acute lymphoblastic leukemia is markedly different. Since th...
Objective: To compare improvement in survival from 1986 to 2009 for acute lymphoblastic leukemia (AL...
INTRODUCTION: Insurance status at diagnosis remains an important barrier to health care access and a...
Identifying sociodemographic disparities in chemotherapy and hematopoietic cell transplantation (HCT...
IntroductionIdentifying sociodemographic disparities in chemotherapy and hematopoietic cell transpla...
Purpose: Limited data exist on intensifying chemotherapy regimens in the treatment of adult acute ly...
PURPOSE: Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children. However, ...
Although the incidence rate of acute lymphoblastic leukaemia (ALL) is slightly higher in older than ...
BACKGROUND: Despite high rate of cure in acute promyelocytic leukemia (APL) in clinical trials, outc...
Introduction:Chemotherapy prolongs survival without substantially impairing quality of life for medi...
Background: Adulthood acute lymphoblastic leukemia (ALL) is a rare disease. In contrast to childhood...
Objectives: Older/elderly patients with acute lymphoblastic leukemia (ALL) are poorly represented in...
International audienceBACKGROUND:Evidences support social inequalities in cancer survival. Studies o...
Background. Acute lymphoblatic leukemia (ALL) shows marked differences in clinical outcome between c...
Acute lymphoblastic leukemia (ALL) has poor prognosis in older/elderly adults and in high-risk/relap...
The outcome of children and adults with acute lymphoblastic leukemia is markedly different. Since th...
Objective: To compare improvement in survival from 1986 to 2009 for acute lymphoblastic leukemia (AL...
INTRODUCTION: Insurance status at diagnosis remains an important barrier to health care access and a...
Identifying sociodemographic disparities in chemotherapy and hematopoietic cell transplantation (HCT...
IntroductionIdentifying sociodemographic disparities in chemotherapy and hematopoietic cell transpla...
Purpose: Limited data exist on intensifying chemotherapy regimens in the treatment of adult acute ly...
PURPOSE: Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children. However, ...
Although the incidence rate of acute lymphoblastic leukaemia (ALL) is slightly higher in older than ...
BACKGROUND: Despite high rate of cure in acute promyelocytic leukemia (APL) in clinical trials, outc...
Introduction:Chemotherapy prolongs survival without substantially impairing quality of life for medi...
Background: Adulthood acute lymphoblastic leukemia (ALL) is a rare disease. In contrast to childhood...
Objectives: Older/elderly patients with acute lymphoblastic leukemia (ALL) are poorly represented in...
International audienceBACKGROUND:Evidences support social inequalities in cancer survival. Studies o...
Background. Acute lymphoblatic leukemia (ALL) shows marked differences in clinical outcome between c...
Acute lymphoblastic leukemia (ALL) has poor prognosis in older/elderly adults and in high-risk/relap...
The outcome of children and adults with acute lymphoblastic leukemia is markedly different. Since th...
Objective: To compare improvement in survival from 1986 to 2009 for acute lymphoblastic leukemia (AL...